COMMUNIQUÉS West-GlobeNewswire

BienRaíz Launches Premium D3 + K2 Formula for Bone Health and Heart Function
04/04/2026
NEW YORK, April 04, 2026 (GLOBE NEWSWIRE) -- As research continues to reveal the critical relationship between vitamin D3 and vitamin K2, BienRaíz—a supplement brand committed to foundational wellness through nature and [...]
Vireo Growth Inc. Partners with Ace Ventures to Establish New York’s First Minority-owned Vertically Integrated Medical Cannabis Operator
04/04/2026
Majority ownership of Vireo Health of New York to transfer to MWBE-led Ace Ventures; partnership reinforces long-term alignment with New York’s social equity framework MINNEAPOLIS, April 03, 2026 (GLOBE NEWSWIRE) -- [...]
VigorX Pro Claims Evaluated: The VitalPro ManForceX Supplementation Method Working for Men Worldwide
04/04/2026
A 2026 informational release covering VigorX Pro's prostate health and male vitality claims, the VitalPro ManForceX supplementation method for men over 40, ingredient research context, pricing structure, 60-day [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today [...]
Overcoming Onychomycosis Claims Evaluated: Blue Heron Health News Nail Fungus Treatment Program is On Sale
03/04/2026
Blue Heron Health News Explains How Scott Davis's Overcoming Onychomycosis Gut-Health and Immune-Support Program Works, What the Digital Guide Includes, Who It May Be Designed For, and How Consumers Can Verify Current [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03/04/2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company [...]
Spyre Therapeutics Announces Grants of Inducement Awards
03/04/2026
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations [...]
Weight Watchers Announces Leadership Transition and Board Updates
03/04/2026
Office of the CEO Established to Oversee Business Operations Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
03/04/2026
BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”) from the NYSE [...]
VitalRIZE Claims Evaluated: The Max Vitalize Virility Enhancement Support Supplement for Men
03/04/2026
A 2026 informational consumer overview of VitalRIZE's male enhancement and virility support positioning, ingredient research context, pricing structure, and what men over 45 should verify before purchasing Aurora, CO, [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
Power Life High Impact Plant Protein Claims Evaluated: The Cleanest Vegan Protein Powder on the Market by PowerLife
03/04/2026
A 2026 informational product overview covering Power Life High Impact Plant Protein ingredient composition, myHMB and Vitamin D3 formulation context, vegan protein powder category positioning, pricing structure, and [...]
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
03/04/2026
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX ® ( [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an [...]
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
03/04/2026
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX ® ( [...]
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
03/04/2026
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology Results from ongoing Phase 1/2 study in patients with FTD-GRN expected by [...]

Pages